Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow, incredible.
How long before we test $28?
Exciting!
IMHO
Very interesting. Thanks for the image.
Found a cleaner image, without the Anavex PDD annotations.
IMHO
anders2211,
This is not hard. Take Biogen for example. Their interpretation differs from others. Reputable and trustworthy scientists on opposite sides of the same results. That is what I am saying.
I am long and believe Missling is not a con artist. But scientists often have opposing opinions. We will see soon enough.
IMHO
Anders2211,
Investor,
No doubt the discussion will focus on SIGMAR1 and the subgroups and its relevance to AD. The question remains, what about the CDR data?
Will that also be presented at CTAD or will the company participate in another conference specific to PD and PDD, to cover the CDR result?
Companies often announce attendance to more than one conference in a single PR, which Anavex has yet to issue (for CTAD even). Perhaps they are finalizing attendance to a second conference and thus the delay in the PR? What are your thoughts on this?
IMHO
Anyone want to comment on why the PR headline included the "Proof of Concept" and "controlled" descriptions? They could have just said "Phase 2" in the headline and mentioned the rest in the body of the article.
Any significance to this?
IMHO
Unfortunately the stock price is reacting to a strong message delivered by a weak messenger.
IMHO
IMO someone squeeze this to hit that $5 calls for tomorrow
I agree.
IMHO
How hard would it be to simply say, "we have completed enrollment for n patients, 50% more than originally planned".
IMHO